ARTICLE | Company News

Roche to acquire Adheron

October 10, 2015 1:32 AM UTC

Roche (SIX:ROG; OTCQX:RHHBY) will acquire Adheron Therapeutics Inc. (Berkeley, Calif.), a developer of technology that disrupts cell adhesion via cell surface protein Cadherin 11 ( Cad-11; CDH11). Adheron is investigating therapies for inflammatory and autoimmune disorders including rheumatoid arthritis and fibrotic diseases.

Adheron shareholders will receive $105 million up front and are eligible for $475 million in milestones. Adheron said it expects the deal to close "shortly." ...